A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of (188)Re-liposome in patients with metastatic tumors

BACKGROUND: Liposomes are drug nano-carriers that are capable of targeting therapeutics to tumor sites because of enhanced permeability retention (EPR). In several preclinical studies with various tumor-bearing mice models, (188)Re-liposome that has been developed by the Institute of Nuclear Energy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shyh-Jen, Huang, Wen-Sheng, Chuang, Chi-Mu, Chang, Chih-Hsien, Lee, Te-Wei, Ting, Gann, Chen, Ming-Huang, Chang, Peter Mu-Hsin, Chao, Ta-Chung, Teng, Hao-Wei, Chao, Yee, Chen, Yuh-Min, Lin, Tzu-Ping, Chang, Ya-Jen, Chen, Su-Jung, Huang, Yuan-Ruei, Lan, Keng-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531516/
https://www.ncbi.nlm.nih.gov/pubmed/31119414
http://dx.doi.org/10.1186/s13550-019-0509-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531516/
https://www.ncbi.nlm.nih.gov/pubmed/31119414
http://dx.doi.org/10.1186/s13550-019-0509-6

Ejemplares similares